New primary monoclonal antibodies
    
        SYnAbs innovative mouse and rat RUO monoclonals to detect MRSA strains targeting PBP2a and PBP2b for diagnosis in lateral flow immunoassay
      
            
        
        MCR-1-mediated colistin resistance detection using SYnAbs monoclonal antibodies
      
    
     
        SYnAbs unique primary monoclonal antibody to specifically detect vancomycin B (vanB) to tackle the threat of antibiotic resistance
      
            
        
        SYnAbs RUO monoclonal antibodies of mouse and rat species highly specific to Estradiol without cross-reactivity to close steroid analogs
      
    
     
        SYnAbs unique specific monoclonal antibodies for the detection of Vancomycin A without cross-reactivity to Vancomycin B or close analogs for antibiotic resistance diagnosis in lateral flow and other immunoassay formats
      
            
        
        SYnAbs unique R&D and therapeutic monoclonal antibodies to CCR10 (GPR-2), C-C chemokine Receptor 10 GPCR transmembrane protein
      
    
     
        SYnAbs offers the complete portfolio of mouse and rat isotype controls IgG1, IgG2a, IgG2b, IgG2c, IgG3, IgA, IgE, IgM
      
            
        
        Valproic acid (VPA) is a widely used drug with narrow therapeutic window, necessitating precise monitoring of blood levels to avoid toxicity or sub-therapeutic effects. Traditional methods of measuring VPA have limitations in terms of sensitivity, specificity, and accuracy. In this context, SYnAbs has developed the best monoclonal antibodies against VPA.
      
    
     
        SYnAbs unique mouse and rat monoclonal antibodies to androstenedione without cross-reactivity to close analogs (DHEA,...)
      
            
        
        SYnAbs develops monoclonals to complex cancer epitopes to be used in theranostic oncology radioimmunotherapy treatments